在非小细胞肺癌中对免疫疗法抵抗机制进行分类:我们如何更好地表现?
Daphne van der Geest1, Alex van Vliet2, Daniel S Peeper2
1Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands d.vd.geest@nki.nl.
免疫检查点抑制剂 (ICI) 对晚期非小细胞肺癌 (NSCLC) 的治疗有前途. 然而,由于抵抗机制,许多患者没有反应,因此需要更好地选择患者以获得更好的结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了高级非小细胞肺癌 (NSCLC) 治疗.
- 然而,大量的NSCLC患者表现出对ICI治疗的原发性或获得性耐药性.
- 对抗药性机制的有限理解阻碍了有效的二线治疗方法的开发.
研究的目的:
- 总结有关NSCLC对ICI耐药性机制的当前知识.
- 提出一种分类系统,根据耐药性概况对患者进行分类.
- 为指导临床前研究和加强临床试验的患者选择.
主要方法:
- 关于NSCLC中ICI耐药性的现有文献的审查.
- 分析拟议的抵抗机制及其相互作用.
- 开发一种新的对抗机制的分类框架.
主要成果:
- 多种复杂的抵抗机制有助于NSCLC的ICI失败.
- 目前对这些机制及其临床影响的理解仍然不完整.
- 缺乏对抗机制的系统分类.
结论:
- 对抗性机制的更深入的理解对于克服NSCLC中ICI失败至关重要.
- 拟议的分类系统可以帮助分层患者进行向治疗.
- 基于耐药性机制的改善患者选择可能会提高临床试验的成功和患者的结果.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
相关概念视频
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
